2 weeks Ago By ABMN Staff
Renaissance Technologies LLC lifted its holdings in Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM – Free Report ) by 67.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission.
The firm owned 101,248 shares of the company’s stock after purchasing an additional 40,800 shares during the period. Renaissance Technologies LLC owned about 0.21% of Mirum Pharmaceuticals worth $4,187,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Jones Financial Companies Lllp raised its position in shares of Mirum Pharmaceuticals by 100.0% during the 4th quarter.
Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after purchasing an additional 357 shares during the period. Legato Capital Management LLC lifted its position in shares of Mirum Pharmaceuticals by 7.9% in the fourth quarter.
Legato Capital Management LLC now owns 13,395 shares of the company’s stock worth $554,000 after buying an additional 977 shares in the last quarter. China Universal Asset Management Co. Ltd.
boosted its stake in Mirum Pharmaceuticals by 10.9% during the fourth quarter. China Universal Asset Management Co.
Ltd. now owns 10,179 shares of the company’s stock valued at $421,000 after buying an additional 1,003 shares during the last quarter. Rhumbline Advisers grew its holdings in Mirum Pharmaceuticals by 2.
4% during the 4th quarter. Rhumbline Advisers now owns 53,113 shares of the company’s stock valued at $2,196,000 after buying an additional 1,236 shares in the last quarter. Finally, Swiss National Bank grew its holdings in shares of Mirum Pharmaceuticals by 1.
9% in the fourth quarter. Swiss National Bank now owns 70,300 shares of the company’s stock valued at $2,907,000 after purchasing an additional 1,300 shares in the last quarter. Mirum Pharmaceuticals Price Performance NASDAQ:MIRM opened at $38.
39 on Tuesday. The firm has a market cap of $1.90 billion, a P/E ratio of -19.
00 and a beta of 1.00. The stock has a 50 day moving average of $44.
98 and a two-hundred day moving average of $44.01. Mirum Pharmaceuticals, Inc.
has a 12 month low of $23.14 and a 12 month high of $54.23.
The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.
33. Wall Street Analysts Forecast Growth A number of research analysts have recently commented on the company. Robert W.
Baird upped their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th.
HC Wainwright boosted their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, February 28th.
Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $58.20.
View Our Latest Analysis on Mirum Pharmaceuticals Insider Transactions at Mirum Pharmaceuticals In other news, SVP Jolanda Howe sold 902 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $43,223.
84. Following the completion of the sale, the senior vice president now owns 3,524 shares in the company, valued at $168,870.08.
This trade represents a 20.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink .
Also, COO Peter Radovich sold 7,879 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $348,330.
59. Following the completion of the transaction, the chief operating officer now directly owns 18,672 shares in the company, valued at approximately $825,489.12.
This trade represents a 29.67 % decrease in their position. The disclosure for this sale can be found here .
Insiders have sold a total of 116,473 shares of company stock worth $5,249,134 in the last ninety days. Insiders own 22.87% of the company’s stock.
Mirum Pharmaceuticals Profile ( Free Report ) Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. Further Reading Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM – Free Report ). Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
